# Federal Cannabis Legalization Bill Returns to the Senate, What Patients and Clinicians Should Watch > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/federal-cannabis-legalization-bill-2026-patients-clinicians-post/ > **Published:** 2026-10-02T21:00:00-04:00 | **Last Modified / Clinically Audited:** 2026-09-17T15:55:11-04:00 > **Clinical Summary:** Senate Democrats reintroduced a federal cannabis descheduling bill in July 2026. Dr. Caplan explains what it would change and why passage remains unlikely. --- CED Clinical Relevance #80 Fresh national cannabis policy and access story Senator Cory Booker announced on July 16, 2026 that Senate Democrats reintroduced the Cannabis Administration and Opportunity Act, a sweeping federal descheduling bill that goes well beyond the administration's narrower Schedule III track. The story matters to CED readers because it touches [patient access](https://cedclinic.com/virginia-cannabis-marketplace-timing/), research, veterans policy, [hemp regulation](https://cedclinic.com/hemp-regulation-product-safety-colorado-thc-inversion-crackdown/), workplace rules, and the difference between a headline proposal and an immediate legal change. Clinical Insight | CED Clinic This is not a passage story, and it is not an immediate access story. It is a federal policy proposal with real downstream clinical implications if it ever becomes law. Senator Cory Booker’s July 16 press release says the bill would remove cannabis from the Controlled Substances Act, create a federal regulatory framework, expand research obligations, direct the Department of Veterans Affairs to study [medical cannabis](https://cedclinic.com/shifting-public-attitudes-toward-cannabis/) in veterans with chronic pain and post-traumatic stress disorder, and protect certain federal benefits and employment rights. Marijuana Moment reported that the reintroduced version also contains new hemp language and would require the attorney general to finalize descheduling within 180 days of enactment. For CED readers, the useful frame is practical: this proposal speaks to where federal cannabis policy could go, but it does not change what a patient, clinician, employer, or state program is allowed to do today. Federal Policy[Cannabis Access](https://cedclinic.com/young-americans-need-to-travel-abroad-to-learn-what-our-generation-had-to-deal-with-to-get-barely-3gs/)ResearchVeteransHemp Rules AudiencePatients, caregivers, clinicians, veterans, cautious consumers, and policy-following readers trying to separate a major federal cannabis proposal from immediate real-world change. Primary TopicA July 16, 2026 national cannabis policy story on Senate Democrats reintroducing the Cannabis Administration and Opportunity Act as a full federal descheduling bill. Source[Read Senator Booker's press release](https://www.booker.senate.gov/news/press/booker-schumer-wyden-reintroduce-legislation-to-end-federal-ban-of-marijuana) Table of Contents - [Federal Cannabis Legalization Bill Returns to the Senate, What Patients and Clinicians Should Watch](#Federal_Cannabis_Legalization_Bill_Returns_to_the_Senate_What_Patients_and_Clinicians_Should_Watch)[How To Read The New Senate Cannabis Bill Without Overreading It](#How_To_Read_The_New_Senate_Cannabis_Bill_Without_Overreading_It)[Four questions worth asking before you overread this bill](#Four_questions_worth_asking_before_you_overread_this_bill) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Today's Rules Still Matter More Than Tomorrow's Promise](#Todayx27s_Rules_Still_Matter_More_Than_Tomorrowx27s_Promise) - [The Bill Is More About Infrastructure Than Efficacy](#The_Bill_Is_More_About_Infrastructure_Than_Efficacy) - [Veterans Provisions Matter, but They Do Not Instantly Change Care](#Veterans_Provisions_Matter_but_They_Do_Not_Instantly_Change_Care) - [Policy Headlines Can Change Household Expectations Fast](#Policy_Headlines_Can_Change_Household_Expectations_Fast) - [This Is An Attempt To Solve More Than Scheduling](#This_Is_An_Attempt_To_Solve_More_Than_Scheduling) - [Serious On Paper Does Not Mean Smooth In Congress](#Serious_On_Paper_Does_Not_Mean_Smooth_In_Congress) - [Employer Rules Will Not Magically Harmonize Overnight](#Employer_Rules_Will_Not_Magically_Harmonize_Overnight) - [Watch Hemp, Research, Veterans, and Worker Provisions](#Watch_Hemp_Research_Veterans_and_Worker_Provisions) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Federal Cannabis Legalization Bill Returns to the Senate, What Patients and Clinicians Should Watch Senate Democrats have reintroduced a broad federal cannabis legalization bill that would do far more than move marijuana to Schedule III. The proposal reaches into research, veterans policy, hemp rules, worker protections, and criminal-record relief. Here is what the bill says, why it matters to CED readers, and what it still does not change today. What This Study Teaches Us This story teaches that federal cannabis reform can move on very different tracks at once. A full descheduling bill is not the same thing as an administrative rescheduling process, and neither one should be mistaken for instant changes in patient access, workplace rules, or clinical evidence quality. Why This Matters Patients and clinicians often hear national cannabis headlines long before the legal and institutional consequences become clear. That is especially risky when federal proposals touch multiple areas at once, such as research, veterans care, hemp-derived THC products, criminal records, federal benefits, and worker protections. If readers overread this bill as a law instead of a proposal, they can make poor assumptions about what changed in their state, their clinic, or their workplace. If they underread it, they can miss a serious sign of where federal cannabis policy may be heading next. Study SnapshotSource TypeOfficial Senate press release with policy-reporting corroborationPublishedJuly 16, 2026What HappenedSenate Democrats reintroduced the Cannabis Administration and Opportunity Act, or CAOALead SponsorsCory Booker, Chuck Schumer, and Ron WydenCore MoveThe bill would remove cannabis from the Controlled Substances Act and create a federal regulatory frameworkResearch ProvisionsThe press release says HHS and NIH research duties would expand and the VA would be required to run clinical trials involving veterans with chronic pain and PTSDPublic Health FramingThe bill would create a Center for Cannabis Products within FDA and direct federal work on labeling, youth-use prevention, and impaired-driving educationHemp AngleMarijuana Moment reported that this version adds language meant to prevent a scheduled federal recriminalization of hemp THC products in NovemberWhat It Does Not Do TodayIt does not itself change current patient permissions, state program rules, or employer drug policiesMain UncertaintyPassage prospects, final bill text changes, and whether Congress or the administration will advance full descheduling ahead of narrower reforms Clinical Bottom Line This is a meaningful federal policy signal, but it is still a proposal. Readers should watch it because it could reshape the long-term framework for cannabis, not because it changed today’s rules by itself. Opening News Brief Senator Cory Booker announced on July 16 that he, Senate Democratic Leader Chuck Schumer, and Senator Ron Wyden reintroduced the Cannabis Administration and Opportunity Act, a sweeping bill that would remove cannabis from the Controlled Substances Act and establish a federal framework for regulation, research, and public-health oversight. The press release says the proposal is meant to end federal prohibition while still keeping state-level choices intact. [Source: Booker press release](https://www.booker.senate.gov/news/press/booker-schumer-wyden-reintroduce-legislation-to-end-federal-ban-of-marijuana). Marijuana Moment reported the reintroduced bill goes beyond symbolic descheduling. The outlet says the measure would require the attorney general to finalize removal of marijuana from the Controlled Substances Act within 180 days of enactment, add a federal tax structure, create a Justice Department Cannabis Justice Office, and include new hemp provisions aimed at blocking a scheduled federal crackdown on hemp THC products later this year. [Source: Marijuana Moment](https://www.marijuanamoment.net/senate-democrats-file-bill-to-fully-legalize-marijuana-under-federal-law-as-trump-moves-to-merely-reclassify-it/). The timing matters. Marijuana Moment also noted that the bill arrived one day after the close of DEA hearing proceedings on the administration’s separate proposal to move marijuana from Schedule I to Schedule III. That makes this a clean example of two different federal reform tracks moving at the same time, one legislative and one administrative. [Source: Marijuana Moment](https://www.marijuanamoment.net/senate-democrats-file-bill-to-fully-legalize-marijuana-under-federal-law-as-trump-moves-to-merely-reclassify-it/). Clinical Perspective The practical value of this story is not that Washington suddenly solved cannabis policy. It did not. The value is that the bill shows what a serious full-framework approach would need to touch if lawmakers ever wanted federal cannabis rules to look coherent: research, labeling, youth protection, veterans, worker rules, banking, benefits, and criminal-record repair. Patients and clinicians should resist two easy mistakes. One is treating this bill as if it already changed care options. The other is dismissing it because it is not law yet. A proposal like this still matters because it signals which gaps federal lawmakers now see as too large to ignore. How This Fits the Bigger Picture Federal cannabis policy has been split between narrow operational fixes and broader legalization goals for years. A Schedule III move can affect research posture, tax treatment, and legal symbolism, but it does not automatically build a retail framework, settle hemp disputes, protect workers, or create a unified public-health system. A full bill like CAOA tries to address those structural gaps all at once. That is why this story has patient relevance even though it is legislative. People do not experience cannabis law as one isolated statute. They experience it through clinic conversations, product labels, job rules, veterans systems, travel, banking, access to regulated products, and the uncertainty around hemp-derived THC items that live in a legal gray zone. What This Does Not Show This story does not show that Congress is close to passage. It does not show that federal agencies, employers, or [state programs](https://cedclinic.com/mississippi-medical-cannabis-program-changes/) have changed their current rules. It does not show that dispensary cannabis now functions like an FDA-approved medication, and it does not show that a descheduling bill would settle every safety, dosing, or impairment question that clinicians face. It also does not prove that every provision described in early coverage will survive intact if the bill moves. Legislative packages change, and politically difficult sections on hemp, taxation, workplace protections, research funding, and criminal-record relief often become pressure points. Key Clinical Caveats No federal cannabis bill changes the basic clinical reality that route, dose, potency, psychiatric vulnerability, cardiovascular risk, delayed edible onset, and product consistency still matter. Policy liberalization and medical appropriateness are not the same question. Readers should also keep product categories separate. A bill that speaks broadly about cannabis, research, or hemp does not make state dispensary products, over-the-counter hemp products, and FDA-approved cannabinoid drugs interchangeable. Those categories still carry different evidence standards, regulatory controls, and counseling needs. Where It Deserves Skepticism The official press release is useful for bill sponsors, stated goals, and major policy categories, but it is still advocacy from the bill’s own backers. That means careful readers should treat it as a primary description of intent, not as neutral proof that the framework is politically viable or perfectly calibrated. [Source: Booker press release](https://www.booker.senate.gov/news/press/booker-schumer-wyden-reintroduce-legislation-to-end-federal-ban-of-marijuana). Marijuana Moment adds more procedural and policy detail, including the hemp provision and the 180-day descheduling timeline after enactment, but those details still belong to a proposal in motion. The strongest skeptical read is not that the bill is trivial. It is that big federal cannabis packages tend to attract support, opposition, amendment pressure, and rhetorical overreach all at once. [Source: Marijuana Moment](https://www.marijuanamoment.net/senate-democrats-file-bill-to-fully-legalize-marijuana-under-federal-law-as-trump-moves-to-merely-reclassify-it/). For Patients and Families The safe takeaway is simple: do not assume this bill changed your rights, your state program, your military status, your employer policy, or your travel risk today. If you are making a personal decision about cannabis, use the rule that actually governs you now, not the rule that might exist later. That said, families who follow cannabis policy should pay attention to the parts of the bill that touch research, labeling, youth prevention, and federal benefits. Those are the areas where long-term federal reform could eventually shape day-to-day decisions in a more concrete way. For Clinicians Clinicians should read this less as a treatment update than as a future-practice signal. If federal lawmakers keep moving in this direction, the pressure will grow for better product regulation, cleaner research pathways, more veteran-focused evidence, and clearer distinctions between state-market products and formal drug development. It is also a reminder to ask patients where their cannabis assumptions are coming from. Legislative headlines often reach patients before sober interpretation does, and that can distort expectations about legality, testing, employment, and medical endorsement. For Cautious Readers A careful reader should avoid the temptation to sort this into either triumph or theater. The proposal is substantial on paper, and it reaches into public health, research, veterans care, and social policy. But it remains a proposal, not a settled national framework. The right question is not whether federal cannabis policy changed in the abstract. It is which specific systems, if any, have changed for you right now. For most readers today, the answer is still none. Policy and Advocacy Angle The bill is notable because it frames federal cannabis reform as more than a criminal-law cleanup. The press release explicitly connects it to public-health regulation, workers’ rights, research capacity, federal benefits, veterans, and reinvestment in communities harmed by prohibition. That is a much wider lens than a simple descheduling debate. [Source: Booker press release](https://www.booker.senate.gov/news/press/booker-schumer-wyden-reintroduce-legislation-to-end-federal-ban-of-marijuana). The policy fight ahead is likely to center on who controls the market, how hemp-derived THC products are treated, how much federal oversight is appropriate, and whether lawmakers can align patient protection with a workable national framework instead of another patchwork compromise. How Strong Is This Evidence? The evidence is strong for a fresh policy explainer because the core event is an official same-day Senate press release naming the sponsors and summarizing the bill’s major public-health, research, and criminal-justice provisions. Marijuana Moment adds same-day reporting on the reintroduced text, including its hemp provisions, descheduling timeline after enactment, and timing relative to the DEA hearing process. The main limitation is that this is legislative intent and early coverage, not enacted law or outcome data. Where This Paper Deserves Skepticism The best skeptical read is that this is a serious proposal with uncertain legislative traction. Readers should take the policy categories seriously while staying cautious about timelines, passage odds, and the assumption that a broad federal framework would move smoothly through Congress without major revisions. What This Paper Does Not Show This story does not show that federal legalization is imminent, that clinicians should change care recommendations today, or that research and product-quality problems are solved by a bill summary. It also does not show how employers, states, insurers, the military, or federal agencies would harmonize their rules in the near term even if the bill advanced. How This Fits With the Broader Clinical Conversation Federal cannabis reform is no longer only a scheduling argument. It now pulls in research design, youth prevention, worker protections, veterans policy, banking, benefits, and hemp regulation. For patients and clinicians, the gap between a national cannabis headline and the rule that applies today remains one of the most important sources of confusion. Dr. Caplan’s Take *I would read this as a map of unresolved federal cannabis problems more than a promise of quick resolution. The sponsors are pointing to the fact that scheduling alone does not answer the questions patients and clinicians actually run into.* *The clinically useful posture is steady skepticism. Watch the bill, learn from the framework, but do not mistake legislative ambition for immediate bedside change.* What a Careful Reader Should Take Away A careful reader should treat this bill as a meaningful federal signal and a poor substitute for today’s rules. It is important because it shows where lawmakers may want cannabis policy to go, not because it already changed what patients or clinicians can safely assume. Evidence Interpretation Guide ## How To Read The New Senate Cannabis Bill Without Overreading It Big cannabis bills can create the illusion that one document has already solved a national policy mess. That is rarely true. A better reading starts by separating what the sponsors want to build from what the country is actually living under today. ### Four questions worth asking before you overread this bill **Is this a law, a rule, or a proposal?**It is a legislative proposal. That matters because its practical significance today is political and directional, not operational. **What makes it broader than a Schedule III move?**The bill reaches into research, veterans policy, worker protections, benefits, youth prevention, hemp disputes, taxation, and federal market oversight. **What is the biggest patient-facing risk in misreading it?**Assuming that a federal headline changed current access, employment, testing, or medical status when those rules often remain exactly where they were yesterday. **What should careful readers watch next?**Watch whether the bill gains traction, which provisions become negotiation targets, and whether Congress continues to treat hemp, veterans, and research as central rather than side issues. The Public Question If lawmakers say they want a full federal cannabis framework, which parts of today’s patchwork are they trying to replace, and which conflicts might still survive? The Patient Question What rule actually governs me today, and am I accidentally letting a future-facing headline shape a present-day decision? The Bottom Line Read this as a roadmap, not as a permission slip. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens OverviewPatients, clinicians, veterans, employers, and policy skeptics will not read this bill the same way because each group is asking a different question about risk, access, evidence, and federal power. #### Today's Rules Still Matter More Than Tomorrow's Promise A patient may hear federal legalization language and assume access or stigma changed immediately. In practice, state rules, employer policies, and clinical judgment still shape most real decisions. That makes restraint more useful than excitement. Lens takeawayA proposal is not a present-day access rule. #### The Bill Is More About Infrastructure Than Efficacy Clinicians should notice the research, labeling, and veterans provisions more than the headline term legalization. Those are the places where a future federal framework could change how evidence is generated and how products are understood. None of that replaces careful patient-specific counseling now. Lens takeawayWatch the framework, but keep present-tense counseling grounded. #### Veterans Provisions Matter, but They Do Not Instantly Change Care The press release says the bill would require VA clinical trials involving chronic pain and PTSD. That is notable because veterans often sit at the intersection of high need, uneven evidence, and restrictive systems. But a trial requirement is still not the same thing as immediate access or endorsement. Lens takeawayVeteran-facing reform can be meaningful without being immediate. #### Policy Headlines Can Change Household Expectations Fast Families may hear that federal legalization is back on the table and assume cannabis has become simpler or safer. In reality, storage, youth exposure, dose confusion, and household rule differences do not disappear with a Senate filing. The home still needs plain boundaries and good information. Lens takeawayNormalization headlines do not replace household caution. #### This Is An Attempt To Solve More Than Scheduling The bill is trying to address the reality that federal cannabis policy has become a patchwork of mismatched systems. Its breadth is the point, and also its political difficulty. The more problems a bill tries to solve, the more pressure points it creates. Lens takeawayBreadth makes the proposal important and vulnerable at the same time. #### Serious On Paper Does Not Mean Smooth In Congress A detailed cannabis bill can still stall, shrink, or fracture when it meets committee politics and coalition limits. Skepticism here should be procedural, not dismissive. The right question is not whether the sponsors are sincere. It is whether the package can survive legislative reality. Lens takeawayTake the framework seriously, and the timeline cautiously. #### Employer Rules Will Not Magically Harmonize Overnight Readers with job-related cannabis concerns should be especially careful not to project future reform into current policy. Testing, safety-sensitive roles, and institutional drug rules often move more slowly than national rhetoric. That lag can create avoidable mistakes. Lens takeawayYour employer manual still beats a Senate press release. #### Watch Hemp, Research, Veterans, and Worker Provisions If this bill moves, the most revealing fights may not be around the word legalization itself. They may center on hemp-derived THC, research obligations, worker protections, and how much federal oversight the market should carry. Those details will show what kind of reform lawmakers can actually agree to. Lens takeawayThe implementation fights will reveal the real federal priorities. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Federal+Cannabis+Legalization+Bill+Returns+to+the+Senate%2C+What+Patients+and+Clinicians+Should+Watch&url=https%3A%2F%2Fcedclinic.com%2Ffederal-cannabis-legalization-bill-2026-patients-clinicians%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Ffederal-cannabis-legalization-bill-2026-patients-clinicians%2F) [BlueSky](https://bsky.app/intent/compose?text=Federal+Cannabis+Legalization+Bill+Returns+to+the+Senate%2C+What+Patients+and+Clinicians+Should+Watch%20https%3A%2F%2Fcedclinic.com%2Ffederal-cannabis-legalization-bill-2026-patients-clinicians%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Booker, Schumer, Wyden Reintroduce Legislation to End Federal Ban of Marijuana](https://www.booker.senate.gov/news/press/booker-schumer-wyden-reintroduce-legislation-to-end-federal-ban-of-marijuana) Related Reading at CED ClinicContinue exploring the evidence[Military Says Marijuana Rescheduling Still Does Not Permit Use by Service Members](https://cedclinic.com/military-marijuana-rescheduling-service-members/) Recent CED context on how federal cannabis headlines can stop short of changing real workplace rules. [Read the military context](https://cedclinic.com/military-marijuana-rescheduling-service-members/)[Texas Hemp Ban Compliance in 2026: Implications for Patients and Clinicians](https://cedclinic.com/2026-texas-hemp-ban-compliance-patients-clinicians/) CED context on how hemp-derived THC rules can diverge sharply from broader cannabis headlines. [Review the hemp rules](https://cedclinic.com/2026-texas-hemp-ban-compliance-patients-clinicians/)[Louisiana THC Drink Makers Brace for the Federal Hemp Ban](https://cedclinic.com/louisiana-thc-drink-makers-federal-hemp-ban/) A related CED explainer on why federal hemp policy shifts matter for access, labeling, and low-dose THC products. [Compare the federal hemp angle](https://cedclinic.com/louisiana-thc-drink-makers-federal-hemp-ban/) ## Frequently Asked Questions What happened on July 16, 2026? Senate Democrats led by Cory Booker, Chuck Schumer, and Ron Wyden reintroduced the Cannabis Administration and Opportunity Act, a bill that would remove cannabis from the Controlled Substances Act and build a broader federal framework. Did this bill legalize cannabis today? No. It is a legislative proposal, not a change in current law. How is this different from moving marijuana to Schedule III? A Schedule III move is a narrower administrative change. This bill aims at full federal descheduling plus broader rules on research, public health, taxes, and market oversight. What did the official press release say about research? The press release said the bill would expand HHS and NIH research duties and require the VA to carry out clinical trials involving veterans with chronic pain and PTSD. Why are hemp products part of this story too? Marijuana Moment reported that this version of the bill includes new language meant to prevent a scheduled federal recriminalization of hemp THC products later this year. Does this change what patients can buy in their state right now? No. State laws, local rules, and current federal policy still govern today's access. Does this mean clinicians should change recommendations now? No. Clinical advice should still rest on current evidence, patient-specific risk, and the rules that actually apply today. Why should cautious readers pay attention if it is only a proposal? Because the bill shows which federal cannabis problems lawmakers are trying to solve, including research, labeling, veterans policy, worker rules, benefits, and hemp regulation. What is the biggest reason not to overread this bill? Large cannabis bills can change substantially or stall entirely, and even successful federal reform does not instantly harmonize every employer, military, state, or clinical rule. What should readers watch next? Watch whether the bill gains real traction in Congress and which provisions, especially around hemp, research, veterans, and worker protections, become the main points of negotiation. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).